Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention

Drug Safety

Volumn 24, Issue 14, 2001, Pages 1039-1053

  Curtis, Michèle G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DROLOXIFENE; ESTROGEN; ETOPOSIDE; FLUOROURACIL; GESTAGEN; IDOXIFENE; KETOCONAZOLE; LETROZOLE; METHOTREXATE; PHENOBARBITAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; WARFARIN;

BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; ENDOMETRIUM CANCER; EYE DISEASE; HORMONE SUBSTITUTION; HUMAN; LIVER TUMOR; NEUROTOXICITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; UTERUS DISEASE; VEIN THROMBOSIS;

EID: 0035675434     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124140-00003     Document Type: Review

References (139)

1. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases
2. A receptor molecule for estrogens: Isolation from the rat uterus and preliminary characterization
3. Hormonal approaches to the chemoprevention of endocrine-dependent tumors
4. Alternate antiestrogens and approaches to the prevention of breast cancer
5. Clinical uses of antiestrogens
6. Clinical pharmacology of selective estrogen receptor modulators
7. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats
8. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
9. Molecular basis of agonism and antagonism in the oestrogen receptor
10. Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene
11. Basic guide to the mechanisms of antiestrogen action
12. Molecular mechanisms of selective estrogen receptor modulator (SERM) action
13. Selective estrogen modulators: A look ahead
14. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer
15. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial
16. 3H]tamoxifen to the 8S estradiol receptor
17. What do we know and what don't we know about tamoxifen in the human uterus
18. Use of tamoxifen for breast cancer: Twenty-eight years later
19. Tamoxifen for early breast cancer: An overview of the randomised trials
20. Current guidelines for the diagnosis and treatment of breast cancer
21. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
22. Interim analysis of the incidence of breast cancer in-the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
23. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women
24. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects
25. In vitro and in vivo binding of toremifene and its metabolites in rat uterus
26. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
27. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer
28. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
29. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer
30. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: A randomized double-blind, the 'nordic' phase III study
31. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer
32. Adjuvant trials of toremifene vs tamoxifen: The European experience
33. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer
34. Raloxifene
35. Raloxifene hydrochloride
36. Multiple binding sites for the anti-estrogen raloxifene (LY 156758)
37. Structure-activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene
38. The effects of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
39. Breast cancer prevention study aims to overcome drug bias [news]
40. Coronary heart disease in women, randomized clinical trials, HERS and RUTH
41. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer
42. Phase 1 trial of droloxifene in patients with metastatic breast cancer
43. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
44. Pfizer droloxifene breast cancer treatment NDA will not be submitted
45. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens
46. Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis
47. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat
48. Tamoxifen and secondary tumours: An update
49. Should clinicians be concerned about the carcinogenic potential of tamoxifen?
50. Toremifene in postmenopausal breast cancer: Efficacy, safety and cost
51. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
52. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
53. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group: Assessment of liver and endometrial cancer risk following tamoxifen
54. Toremifene: Where do we stand?
55. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy
56. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
57. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients
58. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment
59. Gynaecological effects of tamoxifen
60. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening
61. Ovarian cysts in women receiving tamoxifen for breast cancer
62. Questions about tamoxifen and the future use of antiestrogens
63. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
64. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years
65. Tamoxifen: The treatment of choice. Why look for alternatives?
66. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital
67. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: Possible involvement of flavin-containing monooxygenases in tamoxifen activation
68. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes
69. Induction of covalent DNA adducts in rodents by tamoxifen
70. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems
71. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen
72. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
73. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxffen in 1977
74. A risk-benefit assessment of tamoxifen therapy
75. Tamoxifen as adjuvant therapy in breast cancer: Current status
76. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro
77. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts
78. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells)
79. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens
80. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients
81. Tamoxifen and endometrial cancer: Tamoxifen effects on the human female genital tract
82. Endometrial cancer: Incidence, prognostic factors, diagnosis, and treatment
83. Review of the toxicology of tamoxifen
84. Tamoxifen and the uterus and endometrium
85. The Christie hospital adjuvant tamoxifen trial: Status at 10 years
86. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer
87. Risk of endometrial cancer after tamoxifen treatment of breast cancer
88. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice
89. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice
90. Re: Effects of the anti-estrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
91. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies
92. Tamoxifen and mastalgia. An emerging indication
93. Symptoms associated with tamoxifen treatment in postmenopausal women
94. Tamoxifen in postmenopausal women: A safety perspective
95. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer: A phase II study
96. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer
97. Tamoxifen-associated eye disease: A review
98. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity
99. Screening for tamoxifen ocular toxicity: A prospective study
100. Eye problems in breast cancer patients treated with tamoxifen
101. Long-term tamoxifen citrate use and potential ocular toxicity
102. Tamoxifen-induced steatohepatitis
103. Tamoxifen-induced fatty liver in patients with breast cancer
104. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors
105. Hysteroscopic follow-up during tamoxifen treatment
106. The ovary: Cysts, screening, and tamoxifen
107. Guidelines for monitoring patients taking tamoxifen treatment
108. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound
109. Tamoxifen treatment and gynecologic side effects: A review
110. Tamoxifen and endometrial screening
111. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer
112. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy
113. Gynecologic surveillance of women on tamoxifen: First do no harm
114. Life threatening interaction between tamoxifen and warfarin
115. Life threatening interaction between tamoxifen and warfarin
116. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
117. Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma
118. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: An analysis of the tradeoffs
119. Use of aromatase inhibitors in breast carcinoma
120. Superior efficacy of letrozole versus tamoxifen as first-line therapy for post-menopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
121. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: Results of a double-blind randomised phase III trial
122. The potential of aromatase inhibitors in breast cancer prevention
123. Sex steroids and breast cancer prevention
124. Hormonal manipulations may also reduce breast cancer risk
125. Estrogen replacement therapy in breast cancer survivors: A time for change
126. Hormone replacement therapy and breast cancer
127. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
128. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality
129. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women
130. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat
131. Adjuvant therapy in breast cancer. Optimal use in the elderly
132. Practical issues in counseling healthy women about their breast cancer risk and use of tamoxifen citrate